6monon MSN
Zevra signals European expansion for MIPLYFFA as U.S. coverage reaches 66% following robust Q3
Q3 2025 Management View CEO Neil McFarlane highlighted continued momentum for Zevra in Q3, emphasizing "the strong performance of MIPLYFFA, which is delivering meaningful benefits to patients with ...
In addition, Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium, discussing nizubaglustat’s profile and plans for global Phase 3 studies Six presentations will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results